Shamburg News · 8-K filed Oct 19, 2026, 4:10 PM EDT
SpyGlass Pharma Reports Positive 4-Year Interim Data From BIM-IOL System First-in-Human Trial
SGP · SpyGlass Pharma, Inc.
- Other event
- Materiality: medium
SpyGlass Pharma, Inc. announced positive interim 4-year data from its first-in-human trial of the Bimatoprost Drug Pad-IOL System in patients with mild-to-moderate open angle glaucoma or ocular hypertension. The interim data in 21 evaluable patients showed a 37% reduction in mean intraocular pressure, with 86% of patients remaining off all topical IOP-lowering drops and 90% maintaining 20/25 best corrected distance visual acuity. No product-related adverse events were reported.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001778922-26-000052.
Written from the filing by Shamburg Markets. Figures are as reported by the company.